OptraScan - Blogs

OptraSCAN immune-oncology solution for Programmed Death Ligand 1 expression on tumor and immune cells

The field of immune-oncology is exploding dramatically. Immunotherapy agents overcome tumor evasion through targeted immune checkpoint inhibitors and scientifically driven combination therapies including multiple immune-stimulating and chemotherapeutic agents. However, not all patients are benefited from immunotherapy and precision medicine require...
Continue reading
  315 Hits
  0 Comments
315 Hits
0 Comments

Role of digital pathology in improving healthcare in developing nations

Penetration of digital pathology in North America and Europe in research centers, laboratories, and universities is on rise in the recent years. Digital pathology is predicted to follow the successful path of radiology in near future in terms of acceptance. It has been possible due to obvious advantages over conventional microscopy. The possibility...
Continue reading
  456 Hits
  0 Comments
456 Hits
0 Comments

Global TELEPath™ Network

Technological innovations continually nurture the process of globalization and the way we deliver healthcare. Telepathology is one such change of delivering remote pathology services and a value-added clinical benefit for better patient care. With its direct effect on healthcare industry, this new paradigm of international telepathology will facili...
Continue reading
  342 Hits
  0 Comments
342 Hits
0 Comments

Intelligent Digital Pathology

Over the past few years, deep learning, artificial intelligence (AI) and healthcare AI has become a hot topic owing to development of advanced computer-assisted analytical tools. Pathologists too have embraced this revolution with the recent FDA approval of whole slide scanners. The promise of digital pathology is not merely transfer of analog data...
Continue reading
  539 Hits
  0 Comments
539 Hits
0 Comments
 
 
 

Your form has been submitted successfully. We have sent brochure of interest on to your email address.

Thanks for interest! We have sent brochure of interest on to your email address.